Third Harmonic Bio Inc. is a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for allergy and inflammation. The company's principal candidate includes THB001, is a highly selective, oral small-molecule inhibitor of KIT. Third Harmonic Bio Inc. is based in CAMBRIDGE, Mass.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-45.47M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.90 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -19.27% |
| Return on Assets (Trailing 12 Months) | -18.67% |
| Current Ratio (Most Recent Fiscal Quarter) | 54.10 |
| Quick Ratio (Most Recent Fiscal Quarter) | 54.10 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $6.33 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.35 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.09 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.23 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 45.13M |
| Free Float | 42.47M |
| Market Capitalization | $244.82M |
| Average Volume (Last 20 Days) | 0.25M |
| Beta (Past 60 Months) | 2.14 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 93.95% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |